Interleukin-6 plasma levels are modulated by a polymorphism in theNF-κB1gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Interleukin-6 plasma levels are modulated by a polymorphism in theNF-κB1gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma

Published:2011-10-24 Issue:3 Volume:53 Page:411-416
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Giachelia Manuela,Voso Maria Teresa,Tisi Maria Chiara,Martini Maurizio,Bozzoli Valentina,Massini Giuseppina,D'Aló Francesco,Larocca Luigi Maria,Leone Giuseppe,Hohaus Stefan

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.621566

Reference46 articles.

1. Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma

2. Stromal Gene Signatures in Large-B-Cell Lymphomas

3. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma

4. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.

5. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The NF-κB1/p50 Subunit Influences the Notch/IL-6-Driven Expansion of Myeloid-Derived Suppressor Cells in Murine T-Cell Acute Lymphoblastic Leukemia;International Journal of Molecular Sciences;2024-09-13

2. Soluble MIC‐A, IPI, and response to treatment strongly predict survival in patients with germinal center diffuse large B cell lymphoma;European Journal of Haematology;2024-05-14

3. Derangements of immunological proteins in HIV-associated diffuse large B-cell lymphoma: the frequency and prognostic impact;Frontiers in Cellular and Infection Microbiology;2024-04-03

4. Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment;CLIN CANCER RES;2023

5. Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment;Clinical Cancer Research;2023-06-26